Academic · Private company
Parker Institute for Cancer Immunotherapy
Track this companyFree. Adds Parker Institute for Cancer Immunotherapy to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials5
- Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel CombinationsPHASE1 · COMPLETED · started Jun 21, 2019ClinicalTrials.gov NCT03835533 · fetched Nov 12, 2026
- Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome InterventionPHASE1 · COMPLETED · started Jan 28, 2019ClinicalTrials.gov NCT03817125 · fetched Nov 12, 2026
- Nivolumab With or Without Ipilimumab in Advanced Metastatic CancerPHASE2 · COMPLETED · started Oct 17, 2018ClinicalTrials.gov NCT03651271 · fetched Nov 12, 2026
- Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaPHASE1_PHASE2 · COMPLETED · started Jul 21, 2017ClinicalTrials.gov NCT03214250 · fetched Nov 12, 2026
- Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor TherapyPHASE2 · COMPLETED · started Jun 21, 2016ClinicalTrials.gov NCT02731729 · fetched Nov 12, 2026